Last reviewed · How we verify
TAK-536TCH
TAK-536TCH is a small molecule drug that targets the SGLT2 receptor.
TAK-536TCH is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TAK-536TCH |
|---|---|
| Sponsor | Takeda |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors like TAK-536TCH work by blocking the reabsorption of glucose in the kidneys, leading to reduced blood glucose levels. This can be beneficial for patients with type 2 diabetes. By inhibiting SGLT2, TAK-536TCH aims to improve glycemic control and potentially reduce cardiovascular risk.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension (PHASE3)
- A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-536TCH CI brief — competitive landscape report
- TAK-536TCH updates RSS · CI watch RSS
- Takeda portfolio CI